Ohio HB 963: Revise the law governing the practice of physician assistants

Ohio HB 963 appears to be a physician-assistant scope-of-practice bill, but without public bill text the exact changes should be treated as uncertain. Bills in this class typically revise how PAs practice under physician supervision or collaboration, how supervisory agreements are filed or structured, what tasks may be delegated, and how PA prescribing authority is defined. In Ohio, the practical effect could be less about creating a new profession-wide authority and more about changing the administrative rules around PA practice: supervision agreements, chart review, practice-site limits, delegation standards, and whether certain PA decisions require prior physician approval.

For peptide patients, the key issue is whether the bill makes it easier for PAs to serve as primary prescribers in telehealth peptide clinics. PA scope bills often affect supervision-radius or physician-availability rules, which can determine whether a clinic can staff remote patients with PAs across Ohio. Prescribing authority also matters: some peptide-adjacent therapies may involve controlled substances, while many compounded peptides raise separate pharmacy, FDA, and state-board compliance questions. A broader PA prescribing framework would not automatically legalize every compounded peptide protocol, but it could affect who may evaluate, prescribe, refill, or monitor therapy. Off-label prescribing is another watch point: PAs generally operate within delegated authority, standard of care, and board rules, so any change to independent decision-making or physician oversight could directly affect peptide clinics using off-label protocols.

As HB 963 moves through committee, watch for amendments that narrow or expand PA autonomy, especially language on supervision agreements, remote supervision, prescribing schedules, telehealth, chart review, and physician liability. The likely path is through a House health care or occupational licensing committee before any floor vote, with stakeholder testimony from physician groups, PA organizations, medical boards, hospitals, and possibly pharmacy interests. Because the bill was introduced on June 9, 2026 and is still only referred to committee, the near-term timeline will depend on whether hearings are scheduled before the summer recess or held later in the 2026 session.